The successful pharmacokinetic data suggests that Entera Bio's oral GLP-2 peptide tablet is effective in achieving significant systemic exposure in patients with Short Bowel Syndrome. This is a crucial step in the clinical development process, potentially leading to positive trial outcomes, regulatory approval, and commercial success. Given the importance of this development in the company's pipeline, it is likely to have a positive short-term impact on ENTX's stock price.